Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) are inhibitory checkpoints that are commonly seen on activated T cells and have been offered as promising targets for the treatment of cancers. Immune checkpoint inhibitors (ICIs)targeting PD-1, including...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Int J Mol Sci
Main Authors: Kooshkaki, Omid, Derakhshani, Afshin, Hosseinkhani, Negar, Torabi, Mitra, Safaei, Sahar, Brunetti, Oronzo, Racanelli, Vito, Silvestris, Nicola, Baradaran, Behzad
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2020
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7352976/
https://ncbi.nlm.nih.gov/pubmed/32580338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21124427
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki